Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma
Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understoo...
Hlavní autoři: | Berair, R, Pavord, I |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2013
|
Podobné jednotky
-
Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
Autor: Berair, R, a další
Vydáno: (2013) -
Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
Autor: Shrimanker, R, a další
Vydáno: (2017) -
Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
Autor: Xue, L, a další
Vydáno: (2015) -
Interleukin-5 in the Pathophysiology of Severe Asthma
Autor: Corrado Pelaia, a další
Vydáno: (2019-12-01) -
Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma.
Autor: Desai, D, a další
Vydáno: (2013)